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Kasiani C. Myers, Stella M. DaviesBone marrow failure (BMF) syndromes include a broad group of diseases of varying etiologies, in which hem-
atopoeisis is abnormal or completely arrested in one or more cell lines. BMF can be an acquired aplastic ane-
mia (AA) or can be congenital, as part of such syndromes as Fanconi anemia (FA), Diamond Blackfan anemia,
and Schwachman Diamond syndrome (SDS). In this review, we first address the evolution and current status
of bone marrow transplantation (BMT) in the pediatric population in the most common form of BMF, ac-
quired AA. We then discuss pediatric BMT in some of the more common inherited BMF syndromes, with
emphasis on FA, in which experience is greatest. It is important to consider the possibility of a congenital
etiology in every child (and adult) with marrow failure, because identification of an associated syndrome
provides insight into the likely natural history of the disease, as well as prognosis, treatment options for
the patient and family, and long-term sequelae both of the disease itself and its treatment.
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Bone marrow failure (BMF) syndromes include
a broad group of diseases of varying etiologies in which
hematopoeisis is abnormal or completely arrested in
one or more cell lines. BMF can be an acquired aplastic
anemia (AA) or can be congenital, as part of such
syndromes as Fanconi anemia (FA), Diamond Blackfan
anemia (DBA), and Schwachman Diamond syndrome
(SDS). The estimated incidence of BMF is 2 per
million in Europe, with higher rates in Asia, perhaps
resulting from environmental factors [1]. Acquired
AA may occur at any age, and is a serious disease,
with a mortality rate of up to 80% reported in 1979,
when the only treatment option was supportive care
alone [2].
The first successful bone marrow transplantations
(BMTs) were performed in children with severe com-
bined immunodeficiency in 1968; soon thereafter
came attempts at BMT in patients with AA [3]. In
this review, we first address the evolution and current
status of BMT in the pediatric population in the mostDepartment of Pediatrics, Cincinnati Children’s Hospital
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pediatric BMT in some of the more common inherited
BMF syndromes, with emphasis on FA, in which expe-
rience is greatest. It is important to consider the possi-
bility of a congenital etiology in every child (and adult)
with marrow failure, because identification of an asso-
ciated syndrome provides insight into the likely natural
history of the disease, as well as prognosis, treatment
options for the patient and family, and long-term se-
quelae both of the disease itself and its treatment.ACQUIREDAPLASTIC ANEMIA: SUPPORTIVE
CARE AND IMMUNOSUPPRESSION
Initial management of children with marrow fail-
ure often requires transfusion for anemia or thrombo-
cytopenia. Granulocyte colony-stimulating factor
(G-CSF) may be used to induce a temporary rise in
neutrophil counts [4]. These supportive measures do
not change the natural history of the disease, however.
Acquired severe AA (SAA) is thought to result from
immune-mediated destruction of hematopoietic cells,
as a result of aberrant immune activation related to
genetic risk factors and environmental exposures,
such as to infections or drugs [5]. Patients with AA
are classified based on the severity of marrow aplasia,
with a progressively worse prognosis associated with
increasing severity [6]. AA is classified as severe
(SAA) when BM cellularity is\ 25% or between 25
and 50% with \ 30% hematopoietic elements and
\ 500/mm3 granulocytes, \ 20,000/mm3 platelets,
and/or\ 200/mm3 reticulocytes.279
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agents as cyclosporin (CsA) and antithymocyte globu-
lin (ATG) can be effective for children with SAA who
do not have a matched sibling donor. Response rates to
IST in children are favorable, with survival ranging
from 68% in one institution [7] to 80% in another
retrospective study at 10 years, with 89% survival if
the analysis is confined to responders to IST [8]. There
are some concerns regarding immunosuppression,
however. Responses often are slow and incomplete,
and recurrence is common, with only 40% of patients
remaining disease-free at 10 years in one study [9],
leading to the need for long-term IST (often for 2 to
3 years), with its associated side effects. In addition,
there are data demonstrating the risk for malignant
evolution over time with IST therapy, with rates of
myelodysplastic syndrome (MDS)/acute myelogenous
leukemia (AML) ranging from 8% to 25% [10-12].ACQUIRED APLASTIC ANEMIA AND
HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Matched Sibling Stem Cell Transplantation
The prognosis for children with SAA has improved
significantly in recent years. Initial management of
a child with SAA who has an HLA-matched related
donor generally involves hematopoietic stem cell
transplantation (HSCT) [2,13]. Initial attempts at
HSCT for SAA began in the early 1970s, using cyclo-
phosphamide (Cy)-based preparative regimens with
the goal of maximizing immune suppression with lim-
ited myeloablation. Initially, graft rejection occurred
in up to 30% to 60% of patients, limiting success
[14,15]. High rates of graft rejection were largely
from sensitization to donor antigens by multiple previ-
ous blood transfusions, because patients were com-
monly referred for transplantation late in the course
of disease [16-18]. Early transplantations also were
limited by the use of lower marrow cell doses, which
has been associated with increased risk for graft failure
[19]. Perhaps as a consequence of these challenges to
robust engraftment, 54% of recipients demonstrated
mixed donor and host chimerism, putting them at
risk for late graft rejection [20].
The most frequently used preparative regimen for
pediatric patients with SAA undergoing matched
related HSCT is Cy 200 mg/kg, with or without
ATG. There remains some debate regarding the role
of ATG in sibling donor HSCT for SAA, however.
Champlin et al. [21], in a prospective randomized trial
of 341 children and adults, found no statistical differ-
ences in survival, graft failure, or graft-versus-host dis-
ease (GVHD) between patients with SAA undergoing
matched related HSCT receiving Cy alone and those
whose regimen also included ATG. Irradiation gener-ally does not play a role in preparative regimens for
matched related HSCT in SAA. Radiation-based pre-
parative regimes do reduce rejection, but also increase
the risk of acute GVHD (aGVHD), interstitial pneu-
monitis, and malignancy [18]. Current survival rates
have improved such that children are now referred
for transplantation after minimal exposure to blood
products, which has greatly improved (although not
completely solved) the problem of graft rejection
[22-24]. Children with SAA remain at increased risk
for late graft rejection, and immunosuppressive agents
used for GVHD prophylaxis posttransplantation
should be weaned with great caution.
Adequate control of GVHD is essential for a suc-
cessful outcome of HSCT for SAA. In a study of
patients with SAA undergoing matched sibling donor
HSCT, Locatelli et al. [25] reported survival of 98%
in recipients with grade 0-I GVHD, compared with
70% in recipients with grade II-IV aGVHD (P 5\
.005). In agreement with these findings, Locatelli
et al. [25] also reported a survival advantage for the
use of CsA and methotrexate (MTX) compared with
MTX alone as GVHD prophylaxis, a finding generally
supported by others [20,21].
Pediatric survival rates after matched sibling
HSCT for SAA are now excellent, 85% and even
higher in some series [9,18,22,23]. Survival is best in
the youngest children; a European Group for Blood
and Marrow Transplantation (EBMT) study reported
89% survival in children under the age of 10 years. The
important impact of age on outcome is clearly shown
in Figure 1. Similarly, in a single-institution US study,
Kahl et al. [24] reported survival of 88% in a cohort of
81 adults and children with SAA undergoing matched
sibling donor HSCT with a preparative regimen of Cy
and ATG. An EBMT study of adults and children
comparing transplantation and IST for SAA, including
recipients of related and unrelated donor stem cells,
showed an association between improved survival
and younger age, transplantation performed after
1996, a matched sibling donor, a short diagnosis-to-
transplantation interval, and no irradiation in the pre-
parative regimen [22].Stem Cell Sources: BM and Peripheral Blood
Stem Cells (PBSCs)
Recent years have seen an increase in the use of
PBSC grafts for allogeneic transplantations. Most
studies report faster hematopoietic recovery with the
use of PBSCs [26-29]; however, most adult studies
also report an increase in chronic GVHD (cGVHD)
[28-31]. Some adult studies describe improved survival
with PBSCs in adult recipients with high-risk malig-
nancy, although survival generally was no different in
those with standard-risk disease [27-29,32]. Pediatric
reports of PBSC transplantations also describe rapid
Figure 1. Survival after HLA-identical sibling donor BMTaccording to
age. Probability of survival after HLA-identical sibling BMT for acquired
AA is stratified by age at time of transplantation. Data obtained from the
EBMT Register, Severe Aplastic Anemia Working Party, 2003. (Reprin-
ted with permission [23].)
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improved survival seen in some adult studies does
not carry over to the pediatric population, however.
Schrezenmeier et al. [35] reviewed outcomes of almost
700 patients undergoing HLA-matched sibling BMT
for SAA and found that in patients under age 20 years,
significantly increased mortality and cGVHD was as-
sociated with PBSC transplantation. Five-year overall
survival (OS) rate was 73% after PBSC transplantation
and 85% after BMT, with a relative risk of mortality of
2.04 and a relative risk of cGVHD of 2.82 (P 5 .002)
associated with the use of PBSCs [35]. Similar findings
have been reported in children with acute leukemias
undergoing HLA-matched sibling PBSC transplanta-
tion [36].Figure 2. Five-year survival in recipients of unrelated donor transplan-
tations for severe AA before and after 1998. (Reprinted with permission
[50].)SAA: Unrelated Donor Transplantation
Most children with SAA do not have an available
matched sibling donor, and for these children a combi-
nation of IST and aggressive supportive care can be
effective. Response is only partial in some of these chil-
dren, however, and relapse or even malignant evolu-
tion can occur, with only 40% remaining disease-free
at 10 years [9]. Results of a second course of IST are
generally disappointing, with only a 30% overall
response rate with no complete remissions reported
in one study [8]. A recent prospective trial in 52 pedi-
atric patients failing initial IST compared a second
course of IST with those undergoing unrelated donor
HSCT and found an 11% response rate to IST with
a 5-year failure-free survival rate of 9.5% in the former
group, compared with a 84% 5-year failure-free sur-
vival rate in the latter group (P \ .001) [12]. The
EBMT reported that 17% to 36% of SAA patients
treated with IST eventually require HSCT as salvage
therapy [22]. Moreover, a higher risk of clonal evolu-
tion over time is associated with repeat IST [12]. Con-
sequently, many clinicians will proceed with HSCT
from an alternative donor in children with SAA who
have failed one course of immunosuppression [37].Historically, outcomes after alternative donor
transplantation were less favorable than HLA-identi-
cal sibling transplantations, with long-term survival
of only 30% to 40% regardless of the use of mis-
matched family, haploidentical, or matched unrelated
donors [38-41]. The rate of rejection is high in this
population, likely because of in part the heavy transfu-
sion exposure [42]. More intense preparative regimens
are necessary to overcome the HLA barrier for mis-
matched or unrelated grafts and to prevent rejection
resulting from allosensitization after extensive blood
product support, resulting in increased risk of treat-
ment-related mortality (TRM) [43], aGVHD, and
long-term side effects. The risk of rejection can be de-
creased with the addition of irradiation, but this is as-
sociated with significant late effects on growth,
neurocognitive development, pneumonitis, and sec-
ondary malignancy. More recent data show improved
survival in transplantations performed in more recent
years, as shown in Figure 2. This improvement may re-
flect improvements in HLA typing; the availability of
a larger pool of donors as registries have increased in
size, making selection of an 8 of 8 allele matched donor
more likely; modifications to conditioning regimens;
and improvements in supportive care.
Much recent work has focused on optimizing con-
ditioning regimens for patients receiving unrelated
donor transplants for SAA, to minimize toxicity while
protecting against graft rejection. A total body irradia-
tion (TBI) dose-deescalation strategy has been evalu-
ated by Deeg et al. [44] in a randomized trial of
unrelated donor transplantations for SAA. A group of
87 adults and children with SAA who had failed IST
and had no sibling donor underwent conditioning for
HLA-matched or mismatched unrelated donor trans-
plantations. In both thematched andmismatched graft
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together with Cy and ATG, was associated with the
best survival: 61% in the 62 recipients of HLA-
matched donor marrow and 40% in the recipients of
HLA-mismatched unrelated donor marrow. The graft
failure rate was 5%. Survival in patients under age 20
years receiving the optimumTBI dose was even better,
80% at 5 years, approaching that of patients undergo-
ing HLA-identical sibling transplantation [45].
Because the use of TBI has been associated with in-
creased risk of later malignancy, efforts are continuing
to eliminate radiation from preparative regimens. One
approach to improving conditioning in this population
has been the substitution of fludarabine (Flu) in place
of TBI in the preparative regimen for both matched
sibling and unrelated donor transplantations for
SAA. Early results from this approach are encouraging
[46-49]. The EBMT published a series of 38 patients
with SAA receiving unrelated donor or mismatched
family member transplantations [50]. The preparative
regimen included Flu, Cy, and ATG with CsA and
MTX for GVHD prophylaxis. The 2-year OS rate
was 73%, with a rate of 84% in the patients under
age 14 years [46]. Graft rejection was noted in 18%
of patients, grade II-III aGVHD was seen in 11%,
and cGVHD developed in 27%. Although this study
had only a small study sample, this regimen was found
to eliminate the risk of radiation, with a low risk of
GVHD and a moderately low risk of graft failure.
The graft failure rate was significantly higher in older
patients (32% in those over age 14 years vs 5% in
younger patients) [46]. In another small series of 8 chil-
dren with SAA, substitution of Campath 1H for ATG
in combination with high-dose Cy (200 mg/kg) and
low-doseTBI (300 cGy) resulted in 100% engraftment
and survival at 3 years with minimal toxicity [49].
Encouragingly, outcomes of unrelated HSCT for
SAA have improved noticeably in recent years. An
EBMT retrospective analysis of 498 patients with
SAA who underwent transplantation between 1990
and 2005 was designed to determine whether out-
comes had improved and, if so, whether this resulted
from improved donor selection or to improved trans-
plantation technology [51]. This study found a notable
improvement in outcome in patients who underwent
transplantation after 1998, with a relative risk of death
of 0.44 for more recent transplantations, with reduced
risks of graft failure and aGVHD and cGVHD.
Although it was not possible to absolutely determine
the reason for improvement, the authors favored
improved donor matching. In agreement with these
findings, some recent series of young patients (aged
\15 to 20 years) withHLA-matched unrelated donors
found OS rates generally between 70% and 80%, and
as high as 90% in one series [52]. In HSCT with mis-
matched unrelated donors, however, survival remains
less successful, with rates of 34% to 40% [45,50]. Pe-diatric patients who have failed an initial course of
IST should be considered for HSCT if an unrelated
stem cell donor is available. Better outcomes will en-
courage earlier use of HSCT using unrelated donors
and likely further improve survival.
SAA: Unrelated Donor Cord Blood
Transplantation
Experience is limited with unrelated donor cord
blood transplantation (UCBT) for SAA. Graft failure
is a significant risk for patients with SAA, and early
efforts at UCBT for SAA had poor results with high
rates of engraftment failure, attributed to low graft
cell doses and the presence of an intact host immune
system able to reject the graft [53,54]. More recent
efforts with increased immunosuppressive preparative
regimens have produced improved engraftment and
survival in adult populations [55,56], although not
comparable to those in conventional adult unrelated
donor BMT [44]. As might be expected, GVHD is
reduced with UCBT compared with BMT or PBSC
transplantation [56].
Reports of UCBT for SAA in pediatric populations
are limited, but indicate that transplantation can be
successful [51,57,58]. One small retrospective review
of 9 pediatric patients receiving UCBT for SAA after
failure of IST described a 78% actuarial 3-year survival
despite 3 primary graft failures, with 2 patients requir-
ing a second UCBT to achieve satisfactory engraft-
ment [59]. Infections were common in this series,
accentuated by the slower hematologic recovery after
UCBT, with significant viral reactivation (surpris-
ingly, Epstein-Barr virus (EBV), with EBV lympho-
proliferative disease developing in 3 patients). Many
transplantation centers currently reserve UCBT for
children with SAA for those with no other donor
options.HSCT FOR INHERITED BMF SYNDROMES
The possibility that marrow failure results from an
inherited BMF syndrome should be considered for all
patients presenting with AA, regardless of the pres-
ence or absence of characteristic physical findings.
BMF syndromes require specific approaches to man-
agement. Sensitive and specific diagnostic tests, in-
cluding identification of mutations in specific genes,
are available for many disorders, as summarized in
Table 1.
Fanconi Anemia
The most common inherited BMF syndrome, FA
is a complex disorder of increased sensitivity to DNA
damage characterized by congenital anomalies, pro-
gressive BMF, and high risk for MDS, malignant
transformation to acute leukemia, and solid tumors.
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X-linked in a small number of children with bi-allelic
mutations in the FANCB gene. Congenital anomalies
are varied and include limb malformations, thumb
anomalies, renal anomalies (eg, fused pelvic kidneys),
and hydrocephalus. Significantly, a large percentage
of affected persons (25% to 40%) have no visible
anomalies, and FA cannot be excluded without spe-
cific testing for mutagen sensitivity. To date, 13 dif-
ferent genes have been implicated in FA, all of
which play a role in the biochemical pathway of
DNA repair, causing changes in the cells’ ability to
correct double-stranded DNA breaks [60,61]. Inter-
estingly, at least 3 of the known FA genes (FANCN,
FANCD1/BRCA2, and FANCJ) lead to susceptibility
to breast cancer in women with heterozygous muta-
tions, an important consideration when counseling
mothers of affected children, who are obligate het-
erozygotes. Disease manifestations and severity vary
extensively, with some genotype-phenotype correla-
tion and some evidence that genotype may influence
transplantation outcome [62,63]. BMF in FA typically
presents between the ages of 5 and 10 years, with an
actuarial risk of developing BM failure of 50% to
90% by age 40 years [64,65]. The median age of pa-
tients who develop AML is 14 years [66], and the cu-
mulative incidence of hematologic malignancy by age
40 years is 22% to 33% [64,65]. Symptomatic trans-
fusion, G-CSF, and androgens can be used to treat
cytopenias; however, HSCT is the only current defin-
itive therapy to restore normal hematopoiesis.
Preparative regimens for HSCT in FA patients are
modified from standard approaches because of the
chromosomal instability present in all FA cells, includ-
ing nonhematopoietic tissues. Early attempts at
HSCT in FA patients in the 1970s and 1980s were
modeled after HSCT in patients with acquired AA, us-
ing a standard dose of Cy (200 mg/kg). These trans-
plantations had a high mortality rate [67], with many
patients developing severe aGVHD and Cy toxicity,
including severe hemorrhagic cystitis, mucositis, fluid
overload, cardiac failure, and rash. In vitro studies
have shown that FA cells are hypersensitive to DNA
cross-linking agents, such as Cy [68,69]. Patients
with FA also are at increased risk of severe GVHD
compared with patients with severe AA because of
defective DNA repair mechanisms, leading to pro-
longed tissue damage after targeting by an alloreactive
response [70].
Given the historically poor outcomes with stan-
dard-dose Cy, preparative regimens for FA have been
modified significantly, with the goal of limiting toxic-
ity while maintaining engraftment. For those patients
with FA who have an HLA-identical related donor,
early HSCT is now the first-line treatment of choice
for BMF, preferably before transfusion dependence
develops, to limit the risk of graft failure.The development of a successful reduced-intensity
conditioning (RIC) preparative regimen for FA pa-
tients was led by Eliane Gluckman’s group at St Louis,
Paris, who investigated the use of reduced-dose Cy (20
to 40 mg/kg) and reduced-dose thoracoabdominal ir-
radiation or TBI (400 to 450 cGy). Gluckman and col-
leagues [71,72] reported long-term survival of 58.5%
after sibling donor transplantation for FA using this re-
duced dose preparative regimen, although with high
incidences of aGVHD (55%) and cGVHD (70%).
Later series modified the Gluckman regimen with
the addition of ATG, resulting in less aGVHD and
cGVHD and improved survival [71,73,74]. A recent
series of 35 FA patients undergoing matched related
HSCT using this regimen along with peritransplanta-
tion ATG reported an excellent 10-year actuarial sur-
vival of 89%, with aGVHD in 23% of cases and
cGVHD in 12% of cases [75]. An alternative approach
to matched sibling donor transplantation for FA uses
Cy as a single agent. Investigators in Brazil have pro-
gressively decreased the Cy dose, finding that with
a dose of 60 mg/kg, 88% of cases achieve sustained en-
graftment and OS is 93%, with rates of aGVHD and
cGVHDof 17% and 28.5%, respectively [76,77]. A re-
cent retrospective review of experience with matched
related HSCT in FA patients in Saudi Arabia by
Ayas et al. [78] found significantly greater OS in pa-
tients receiving nonradiation, low-dose Cy and ATG
regimens compared with those undergoing preparative
regimens with Cy and additional thoracoabdominal
radiation (72.5% vs 96.9%; P 5 .013).
An important goal in current preparative regimens
is the elimination of radiation because of the increased
risk of posttransplantation malignancy in this DNA
damage–sensitive population [65]. The availability of
Flu, a highly immunosuppressive nucleoside analog
that is well tolerated by patients with FA, has allowed
the elimination of radiation with good results [79-
83]. Tan et al. [80] recently reported an actual OS of
82%, TRM of 9%, and minimal GVHD in a cohort
of 11 patients who underwent transplantation with
low-dose Cy, Flu, and ATG with T cell–depleted
BM or umbilical cord cells. Longer follow-up times
are needed to fully evaluate whether this conditioning
regimen can reduce the risk of later malignancy after
matched related HSCT in the FA population.
Because most persons with FA requiring trans-
plantation do not have a healthy matched related
donor, unrelated donor HSCT remains a key treat-
ment strategy in FA. Historically, outcomes of alterna-
tive donor transplantations in FA, typically using 40
mg/kg of Cy and 450 cGy of TBI, have been quite dis-
couraging, with high incidences of graft failure,
aGVHD and cGVHD, and organ toxicity related to
preparative regimens. OS has been approximately
30% to 40%, with TRM rates of 70% to 80%
[62,71,84], leading to referral of patients in the most
Table I. Characteristics of hereditary bone marrow failure syndromes
Disease Gene Inheritance Relative frequency Screening/Diagnostic tests Clinical expression
Fanconi Anemia FANC A AR 57-66% MMC, DEB chromosomal breakage Aplastic anemia, malformations: micropthalmia,
short stature, thumbs/radii, cafe au lait spots,
genitourinary etc.
FANC B XLR Rare
FANC C AR 10-15% FANC D2 ubiquitination Malignancies: AML, squamous cell carcinoma of
the head and neck, urogenital track, liver or
other organs
FANC D1/BRCA2 AR 2-4%
FANC D2 AR 2%
FANC E AR Rare
FANC F AR 2%
FANCG/XRCC9 AR 9%
FANCI AR Rare
FANCJ/BACH1/BRIP1 AR 2%
FANCL/PHF9/POG AR Rare
FANC M/Hef AR Rare
FANCN/PALB2 AR 2%
Schwachman Diamond Syndrom (SDS) SBDS AR 95% Decreased serum trypsinogen and/or pancreatic
isoamylase
Aplastic anemia, pancreatic exocrine deficiency
Dyskeratosis Congenita (DC) DCK1 XLR 30% Telomere length Aplastic anemia, dysplastic nails, reticulated
pigmentation, malformations, cancerTERC AD <5%
TERT AR <5%
TINF2 AR 11%
NOP10 AR Rare
NHP2 AR Rare
? AR
Amegakaryocytic Thrombocytopenia (CAMT) c-Mpl AR 100% None Amegakaryocytosis, aplastic anemia
Diamond Blackfan Anemia (DBA) RPS19 AD 25% Elevated adenosine deaminase Erythroblastopenia, rare aplastic
anemiamalformations: craniofacial,
urogenital, cardiac, thumb anomalies
RPS24 AD 2%
RSP17 AD 2%
RPL5 AD 10%
RPL11 AD 6.50%
RPL35A AD 2%
Severe Congential neutropenia ELA2 AD 60-80% Severe infections in infancy
WAS XLR
GFI1 AD 2%
Thrombocytopenia Absent Radii (TAR) ? Bigenic AR Absent radii/abnormal ulnae/humeri cardiac,
renal malformation
Kostmann Syndrome HAX1 AR
AD indicates Autosomal dominant; XLR, X-linked recessive; MMC, Mitomycin C; DEB, diepoxybutane; AML, acutemyelogenous leukemia; CAMT, Congenital amegakaryocytic thrombocytopenia; AA, aplastic anemia.
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Figure 3. Probability of overall survival of unrelated donor transplan-
tation with fludarabine and nonfludarabine regimens in FA patients after
adjusting for previous red blood cell transfusions and cytomegalovirus
serostatus. (Reprinted with permission [63].)
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outcomes. In an attempt to improve engraftment,
MacMillan et al. [84] escalated the radiation dose to
600 cGy and added ATG; this decreased the incidence
of aGVHD and cGVHD, but did not improve OS,
however.
The advent of Flu-based preparative regimens has
resulted in considerable progress, improving engraft-
ment without significant toxicity attributable to the
drug. Reported survival rates with Flu-containing
preparative regimens range from 38% to 96%
[63,79,85-88]. In a large retrospective study of 98
alternative donor transplantations for FA through the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR), Wagner et al. [63] re-
ported that Flu-containing regimens were associated
with improved engraftment and decreased TRM (to
47% from 81%), with a 3-year OS of 52% for Flu-
containing regimens and 13% for Flu-free regimens
(P\ .001) (Figure 3).
A proportion of FA patients experience mosaicism,
with some lymphocytes exhibiting a typical mutagen-
sensitive phenotype and some exhibiting a normal
response to mutagens. Mosaicism raises the concern
that the RIC preparative regimen used for FA patients
may be insufficient to eradicate the population of lym-
phocytes with normal response to mutagens that
would then reject the graft. In the CIBMTR series,
an increased risk of graft failure for transplant recipi-
ents with mosaicism was confirmed in the patients
who underwent transplantation using preparative
regimens without Flu, but not in those using a Flu-
containing regimen [63].
FA patients tolerate GVHD tissue damage poorly,
and GVHD likely increases the risk of later malig-
nancy [72,89]. The incidence of GVHD in FA patients
has been reduced by T cell depletion of alternative
donor and matched related donor HSCT in FA
[77,80,87]. Wagner et al. [63] reported that in the
CIBMTR study, the use of T cell–depleted stem cell
sources reduced the incidence of aGVHD from 71%
to 21% in the absence of Flu and to 16% with Flu.
The incidence of cGVHD in the CIBMTR study pop-
ulation remained high at 31%, regardless of condition-
ing regimen or GVHD prophylaxis, which remains
a concern. In contrast to this report, a cohort of 27 Jap-
anese patients with FA receiving unrelated donor
HSCT with a Flu-containing preparative regimen
and non–T cell–depleted grafts demonstrated an
even lower rate of aGVHD than reported by Wagner
at al. [85]. This may reflect greater genetic homogene-
ity between Japanese unrelated donors and recipients,
or it may indicate that T cell depletion is not essential
to decrease the incidence of GVHD, as reported in
other small series [81].
Although Flu regimens have had some success in
treating FA, concerns regarding RIC regimens persist;residual FA cells that survive the preparative regimen
may present as AML as much as 10 years later
[71,75]. Despite these data, however, Chaudhury
et al. [87], in a study of 18 high-risk patients with trans-
fusion-dependent AA, MDS, and AML receiving ei-
ther related mismatched or unrelated matched or
mismatchedHSCTusing Flu, TBI, andCy for prepar-
ative regimens with T cell–depleted stem cell sources,
found 100% engraftment, OS of 72.2%, and disease-
free survival (DFS) of 66.6% with a median follow-
up of 4.2 years, suggesting that an RIC preparative
regimen might be sufficient to control malignancy in
FA. Long-term follow-up is needed to fully the evalu-
ate risk of late malignancy in all of these populations,
however.
Cord blood is an alternative stem cell source for
patients with FA who lack an HLA-matched unre-
lated BM donor. The decreased incidence of
GVHD with UCBT is attractive for the FA popula-
tion, who is at significant risk from this complication.
In a retrospective review of 93 FA patients who un-
derwent UCBT, Gluckman et al. [90] found an OS
of 40% and incidences of aGVHD and cGVHD of
32.5% and 16%, respectively. Patients in this series
who underwent transplantation with a Flu-containing
regimen had improved engraftment compared with
those who received other regimens (72% vs 42%),
as well as improved OS (50% vs 25%) (Figure 4).
UCBT is indicated in FA patients with rare tissue
types in whom an unrelated marrow donor cannot
be identified.
Despite the improved survival, identifying the
ideal time for HSCT in FA patients requiring alterna-
tive donor transplantations remains challenging, given
the still-significant peritransplantation mortality and
the possibility of long-lasting androgen response or
survival with AA for a significant period without pro-
gression to MDS/AML. Referral and transplantation
before exposure to large amounts of blood products
or prolonged periods of severe neutropenia are likely
to lead to the best outcomes. Current trends for
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of earlier transplantation using unrelated donors,
which likely will further improve survival.
Shwachman-Diamond Syndrome
SDS is a rare autosomal recessive disorder charac-
terized by exocrine pancreatic insufficiency, skeletal
abnormalities, and BMF, with a predisposition to
MDS and leukemia, especially AML. Almost all per-
sons with SDS have a mutation in the SBDS gene on
chromosome 7q11 [91]. Although most persons with
SDS have some hematologic abnormalities, most of
them do not require transplantation. Approximately
20% of SDS patients develop AA, 20% to 33%develop
MDS or cytogenetic abnormalities, and 12% to 25%
will eventually transform into acute leukemia [92-95].
Survival after HSCT using a fully myeloablative
preparative regimen, with a matched sibling or unre-
lated donor, is approximately 60% [96,97]. Most
deaths are related toMDS, leukemia, or organ toxicity,
including cardiotoxicity from Cy and neurologic and
pulmonary toxicities [97-102]. In a review of the Euro-
pean experience with HSCT in SDS, Cesaro et al. [98]
reported a similarly high TRM rate of 35.5%, with
a significantly higher rate in patients receiving
a TBI-containing regimen (67% vs 20% for those
receiving a non–TBI-containing regimen; P 5 .03).
Although the number of patients is very small, those
patients who undergo transplantation for aplasia have
better outcomes than those who undergo transplanta-
tion for MDS or leukemia [102]. More recently, small
series using RIC preparative regimens have demon-
strated improved outcomes [96,103,104]. A recent se-
ries of 7 SDS patients with marrow aplasia or MDS/Figure 4. Survival of 93 FA patients who underwent UCBT according
to the use of fludarabine in the conditioning regimen. (Reprinted with
permission [90].)AML who underwent matched related or unrelated
donor HSCT after a preparative regimen comprising
Campath, Flu, and melphalan (Mel) reported 100%
engraftment and 100% survival, withminimal morbid-
ity [104].
Dyskeratosis Congenita
Dyskeratosis congenita (DC) is a disorder of di-
verse inheritance with chromosomal instability related
to a defect in telomere maintenance [105], character-
ized by a classic triad of reticulate skin pigmentation,
mucosal leukoplakia, and nail dystrophy, along with
BMF. Between 80% and 90% of persons with DC
will develop hematopoietic abnormalities by age 30
years, and BMF is the leading cause of early mortality
in this population [106,107]. In addition, DC patients
are at increased risk for MDS/AML and solid tumors,
especially squamous cell carcinomas [106,108,109], as
well as progressive pulmonary fibrosis [106,107].
Androgens, such as oxymetholone, can produce some
improvement in hematopoietic function for some
DC patients for varying periods; however, HSCT is
the only curative therapy for BMF. Initial attempts at
HSCT in DC patients with myeloablative regimens
had poor results, with significant morbidity and mor-
tality, including increased incidences of chronic pul-
monary and vascular complications [109-113], likely
related to these patients’ underlying tendency to
develop restrictive pulmonary disease. Mortality rates
ranged from 50% to 85% in one review of the litera-
ture; keep in mind that the number of reported cases
is very small, however [109]. More recent nonmyeloa-
blative transplantations using low-dose Cy or Flu and
ATG have produced successful engraftment and good
short-term outcomes, largely in case reports [109,113-
115]. Although these results are encouraging, longer
follow-up is needed to identify further patterns of tox-
icity from these low-intensity regimens in this difficult
population, because many deaths from pulmonary and
vascular complications occur some years after trans-
plantation.
Diamond-Blackfan Anemia
DBA is a rare inherited form of pure red blood cell
aplasia that presents early in infancy. Mutations in one
of a number of ribosomal proteins have been identified
in approximately 50% of DBA patients, implicating
ribosomal biogenesis or function in the disorder
[116]. Clinically, DBA is associated with macrocytosis,
reticulocytopenia, and normal marrow cellularity with
erythroblastopenia. Characteristically these patients
have elevated fetal hemoglobin and erythrocyte aden-
osine deaminase activity, and up to 35% have an asso-
ciated congenital anomaly, with craniofacial and
thumb abnormalities themost common [117]. A subset
of DBA patients (15% to 50%) will develop other
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remain the mainstay of initial therapy in DBA, with
a response rate of approximately 80%. But only 20%
of patients achieve remission; 40% require continued
therapy with steroids, which can have significant side
effects, and another 40% remain transfusion- and che-
lation-dependent [116].
Steroid-intolerant or transfusion-dependent pa-
tients may be considered for HSCT, which, although
curative for DBA, remains controversial, because
most of these patients can achieve long-term survival
with supportive therapy alone. A series of 36 patients
from the Diamond-Blackfan Anemia Registry
(DBAR) who underwent HSCT (predominantly for
transfusion dependence) yielded 5-year survival rates
of 72.7% in matched sibling donor recipients and
19.1% in alternative donor recipients (P 5 .01)
[120]. Similar results were reported in an International
BoneMarrowTransplant Registry series of 61 patients
with DBA undergoing HSCT with conventional Cy-
containing preparative regimens; 3-year survival was
76% after sibling donor transplantation, compared
with 39% after alternative donor transplantation
[121]. In both studies, the alternative donor recipients
were more likely to have received a TBI-containing
regimen or to have a longer time from diagnosis to
transplantation, and an overlap of cases between the
2 series is possible.
A recent Japanese registry series of 19 cases found
improved survival in the 7 unrelated donor marrow re-
cipients (all of whom survived), but poorer outcomes
in the 3 unrelated donor cord blood recipients, 2 of
whom experienced graft failure and 1 of whom dies be-
cause of TRM [122]. That study found no difference
between regimens containing only TBI or only che-
motherapy. Whether the limited HLA diversity seen
in Japanese populations might have contributed to
the good outcomes reported in this study is difficult
to discern. There also are encouraging case reports
of successful HSCT in DBA with RIC Flu containing
preparative regimens; however, the data are scanty and
reflect short follow-up times; further study is needed in
this area [123,124].
The risk of malignancy is lower in DBA compared
with some other hereditary BMF syndromes, such as
FA, but greater than that in the general population.
In a recent update of a cohort of 700 patients, 4% had
been diagnosed with cancer at amedian age of 15 years,
a significantly higher rate than that in non-DBA age-
matched controls [116]. Most of the reported malig-
nancies were AML (although 1 acute lymphoblastic
leukemia (ALL) case was reported), with 3 cases of
MDS that did not progress to leukemia. Sarcomas
were also reported, including 5 osteogenic sarcomas
and 1 soft tissue sarcoma, as were various other cancers,
including Hodgkin lymphoma, breast cancer, hepato-
cellular carcinoma, and other solid tumors [116,125].One patient with DBA who underwent alternative do-
nor transplantation with a TBI-containing preparative
regimen developed metastatic osteosarcoma and died
on day 1571 posttransplantation [126]. Given the pre-
dilection of DBA patients to malignancy, the use of ra-
diation-free preparative regimens in this population
before transplantation should be considered.
Congenital Amegakaryocytic
Thrombocytopenia
Congenital amegakaryocytic thrombocytopenia
(CAMT) is a rare autosomal recessive disorder caused
by mutations in the thrombopoietin receptor MPL
[127]. CAMT is usually diagnosed early in childhood,
presentingwith isolatednonimmune thrombocytopenia
with decreasedmarrowmegakaryocytes. Approximately
50% of CAMT patients develop marrow aplasia, and
some develop MDS or leukemia [128]. Although tran-
sient responses to steroids, CSA, and growth factors in
CAMT have been documented, HSCT remains the
only curative treatment. Good short-term survival has
been reported after matched related donor transplanta-
tion in small case series. Reports of unrelated donor
transplantations are largely case reports and describe
significant engraftment challenges [129-134].LATE EFFECTS AFTER HSCT
Secondary malignancies are an important and
well-documented late effect after HSCT. Susceptibil-
ity varies widely depending on the underlying etiology
of BMF. Many patients with inherited BMF syn-
dromes are already at increased risk for malignancy be-
fore HSCT. The best documented example of this are
patients with FA, who are at greatly increased risk for
solid tumors, such as head and neck squamous cell car-
cinoma, gynecologic squamous cell carcinoma, and
esophageal carcinoma, in addition to skin, brain, liver,
and renal tumors even without transplantation involv-
ing exposure to high doses of DNA-damaging agents
such as Cy and radiation [64,66,135]. The cumulative
incidence of solid malignancy by age 50 years in the
German Fanconi Anemia Registry is 28% [65].
HSCT cures the BMF in FA patients, but also in-
creases the risk of solid tumors by 4-fold and shifts
risk of tumor development to 16 years earlier [65,89].
Approximately 40% of FA patients developing malig-
nancy within 15 to 20 years post-HSCT [136], al-
though it should be kept in mind that persons with
FA who survive without requiring transplantation for
BMF may have a different phenotype than those who
do require transplantation. GVHD is a key risk factor
for the development of late tumors posttransplantation
in FA patients [72,89]. Guardiola et al. [70] reported
a 28% incidence of head and neck cancers 10 years
post-HSCT in those with history of aGVHD versus
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the importance of developing RIC regimens and strat-
egies, such as T cell depletion, to help minimize
GVHD.
Patients undergoing HSCT for acquired AA also
are at significant risk for secondary malignancy, most
commonly carcinoma of the skin and oral mucosa
[137,138]. Major risk factors that have been identified
are the development of cGVHD and the use of radia-
tion-based conditioning regimens, although patients
who do not receive radiation may remain at higher
risk compared with the general population [136,139].
In one series of 700 patients reporting outcomes 20
years after myeloablative transplantation for SAA, the
Kaplan-Meier estimate of risk of secondary malig-
nancy post-HSCT for SAA was 14% [136].
Although transient ovarian and testicular dysfunc-
tion are common after Cy-based HSCT conditioning
therapy in patients with AA, children who receive
non–TBI-containing transplantation regimens for ac-
quired AA demonstrate normal growth, with attainment
of final adult height close to that predicted from paren-
tal height, normal thyroid and adrenal function, and
preserved fertility [136,137,140-143]. The more inten-
sive alternative donor regimens are associated with
more late adverse effects. Along with the increased
risk of malignancy, as discussed earlier, radiation-
based myeloablative regimens have been shown to re-
duce final adult height and lead to abnormal thyroid
function and often-irreversible gonadal failure. Late
adverse effects still occur even in patients receiving ra-
diation therapy that spares the neuroendocrine axis
and focuses mainly on lymphoid tissues. Regardless
of the preparative regimen used, all patients undergo-
ing BMT should receive routine monitoring of growth
and development, endocrine and pulmonary function,
and bone marrow density, and patients receiving radi-
ation-containing regimens should receive fertility
counseling as well.
GVHD and its consequences continue to pose ma-
jor challenges after HSCT in AA patients. Despite
improved preparative regimens and the use of calci-
neurin inhibitors and T cell depletion for GVHD pro-
phylaxis, the incidence of cGVHD remains significant,
particularly after alternative donor transplantations
[143]. cGVHD results in decreased quality of life and
survival, and continued efforts to improve prophylaxis
and treatment are important [136,137].
Various other complications can occur afterHCST
for BMF. One study reported restrictive or obstructive
pulmonary disease in 24% of patients, particularly in
those with a history of cGVHD [137]. Pulmonary fail-
ure was a significant cause of late mortality posttrans-
plantation. Aseptic necrosis or severe osteoporosis is
also common after HSCT. Neurocognitive effects are
more likely to occur in children who are very young
(aged\3 years) at the time of transplantation [144].CONCLUSION
Significant advances have been made in the use of
HSCT to treat both acquired and inherited AA. Out-
comes for matched sibling HSCT for inherited and
acquired BMF syndromes are good, and prompt
HSCT is the treatment of choice for patients with
available matched related donors. Although outcomes
with unrelated donor HSCT are improving, toxicity
remains significant. The available data support the
use of unrelated donor HSCT in children with ac-
quired SAA who do not respond to a course of IST
or who relapse after IST. The improved outcomes of
unrelated donor HSCT in children with FA who
receive a Flu-based preparative regimen has resulted
in children now being referred as soon as they need
transfusion, which likely will improve survival even
further. The indications for transplantation in other
BMF syndromes remain poorly defined because of
phenotypic variability and a paucity of data, and the
decision of whether of not to perform transplantation
must be individualized for each child. AGVHD and
cGVHD poses major challenges to the success of
HSCT for BMF, being associated with many of the
late complications of transplantation. The advent of
RIC preparative regimens, such as lower-dose irradia-
tion and Flu-based strategies, for a wider range of dis-
orders beyond FA shows promise in improving
outcomes and may decrease some of the long-term
complications associated with intensive preparative
regimens. Maintaining a high index of suspicion for in-
herited etiologies of BMF remains crucial in patients
with SAA, even those presenting beyond childhood;
the natural history of the disorder may vary widely,
and a unique approach to management and frequent
adjustment to the preparative regimen before HSCT
may be needed.ACKNOWLEDGMENTS
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